CYP4F2 acts primarily as an enzyme that converts arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a metabolite involved in the regulation of blood pressure in humans. The aim of the present study was to assess the association between the human CYP4F2 gene and essential hypertension (EH) using a haplotype-based case-control study that included separate analysis of the two gender groups. The 249 EH patients and 238 age-matched controls were genotyped for 5 single-nucleotide polymorphisms (SNPs) of the human CYP4F2 gene (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200). Data were analyzed for 3 separate groups: all subjects, and men and women separately. For the total population and for male subjects, the distribution of the dominant model of rs1558139 (CC vs. CT + TT) differed significantly between the EH patients and control subjects (p =0.037 and p =0.005, respectively), with a higher percentage of EH patients showing the CC genotype. Logistic regression showed that, for men, the CC genotype of rs1558139 was more prevalent in the EH patients than in the control subjects (p =0.026), while, for the total population, the difference disappeared (p =0.247). For men, the overall distribution of the haplotypes was significantly different between the EH patients and the control subjects (p =0.042), and the frequency of the T-T-G haplotype was also significantly lower for EH patients than for control subjects (p =0.009). In conclusion, the present results indicate that rs1558139 might be a genetic marker for EH and the T-T-G haplotype might be a protective genetic marker for EH in Japanese men. (Hypertens Res 2008; 31: 1719-1726)
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Introduction
Essential hypertension (EH) is a major risk factor for many common causes of morbidity and mortality including stroke, myocardial infarction, congestive heart failure, and end-stage renal disease (1) . The etiology and pathogenesis of EH are likely comprised of a multifactorial disorder that results from the inheritance of several susceptibility genes as well as from multiple environmental determinants. A variety of gene variants have been shown to be associated with EH (2) .
Cytochrome P450 (CYP) is a superfamily of cysteinato-heme enzymes that are not only involved in the metabolism of xenobiotics, but also metabolize a host of endobiotics. CYP enzymes are classified into families, subfamilies, and individual isoenzymes, based on similarities in their amino acid sequence (3) . To date, the 5 human CYP4F members that have been identified are CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12, all of which are located on chromosome 19 (4) . The CYP4F2 gene is located at 19pter-p13.11, spans approximately 20 kbp, and contains 13 exons. The CYP4F2 family is expressed at high levels in the kidney and liver and is involved not only in the metabolism of leukotriene B4 but also arachidonic acid (AA) (5) . CYP4F2 converts AA to 20-hydroxyeicosatetraenoic acid (20-HETE), which exhibits potent biological effects on renal tubular and vascular functions and on the long-term control of arterial pressure (6) . It has been well established that alterations in renal 20-HETE production contribute to the development of hypertension in both rodent models and humans (7, 8) . Recently, Stec et al. identified a functional variant in the human CYP4F2 gene (rs2108622, V433M) that results in a decrease in 20-HETE production from AA (9) . However, large, population-based studies are needed to determine whether the functional variants of the CYP4F2 gene are related to hypertension. Given the potential importance of 20-HETE in the regulation of hypertension, the aim of the present study was to assess the association between EH and the human CYP4F2 gene in Japanese subjects using a haplotype-based case-control method.
Methods

Subjects
Subjects diagnosed with EH were recruited at Nihon University Itabashi Hospital and other neighboring hospitals in Tokyo from 1993 to 2003. A total of 249 EH patients were enrolled in the present study, with a male/female (m/f) ratio of 1.94. EH was diagnosed based on the following criteria: seated systolic blood pressure (SBP)> 160 mmHg or diastolic blood pressure (DBP)> 100 mmHg on 3 occasions within 2 months after the first blood pressure (BP) reading. None of the EH patients were receiving antihypertensive medication and patients diagnosed with secondary hypertension were excluded. A total of 238 normotensive (NT) age-matched individuals (m/f ratio= 1.88) were enrolled as control subjects. Controls were members of the New Elder Citizen Movement in Japan, and all subjects lived in Tokyo or the suburbs of Tokyo. All controls were confirmed to have grade 0 on the modified Rankin Scale. In this study group, participants with cancer or autoimmune diseases were excluded. None of the control subjects had a family history of hypertension, and all had a SBP of < 130 mmHg and a DBP of < 85 mmHg. The sample size was thought to be large enough because our previous studies successfully isolated EH susceptibility markers using a similar sample size (10, 11) . Informed consent was obtained from each subject in accordance with the protocol approved by the Human Studies Committee of Nihon University.
Genotyping
There are 225 single-nucleotide polymorphisms (SNPs) for the human CYP4F2 gene listed in the National Center for Biotechnology Information SNP database Build 126 (http:// www.ncbi.nlm.nih.gov/SNP). We screened the data for the Tag SNPs on the International HapMap Project website (http://www.hapmap.org/index.html.ja) and used a cut off level of r 2 ≥ 0.5, along with a cut off level of ≤ 0.1 for the minor allele frequency (MAF). According to the above criteria we selected rs3093135, rs1558139, and rs2108622 as SNPs for this gene. rs3093135 and rs1558139 were located in introns, and rs2108622 was located in an exon with a nonsyn- Fig. 1 (9) . In the current study, we also looked at rs3093105 and rs3093200, which are located in the exons and are known to be nonsynonymous SNPs. We designated these SNPs as SNP1 (rs3093105), SNP2 (rs3093135, C_27482167_10), SNP3 (rs1558139, C_2583813_10), SNP4 (rs2108622, C_16179493_40), and SNP5 (rs3093200), in order of increasing distance from the 5′ end of the gene (Fig.  1) . SNP2, SNP3 and SNP4 were genotyped using a kit from Applied Biosystems Inc. (ABI; Foster City, USA). Since SNP1 and SNP5 were not registered in the genotyping kit from ABI, we purchased and used a Custom TaqMan ® SNP Genotyping Assay for these SNPs. Blood samples were collected from all participants, and genomic DNA was extracted from the peripheral blood leukocytes by phenol and chloroform extraction.
Genotyping was performed using the TaqMan ® SNP Geno- (40 ×), primers at a concentration of 331 nmol/L each, and probes at a final concentration of 73.6 nmol/L each. Thermal cycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s, and 62°C for 1 min. Thermal cycling was performed using the GeneAmp 9700™ system. Each 96-well plate contained 80 DNA samples of an unknown genotype and 4 reaction mixtures containing reagents but no DNA (control). The control samples without DNA are a necessary part of the Sequence Detection System (SDS) 7700™ signal processing, as outlined in the TaqMan Allelic Discrimination Guide (ABI). The plates were read on the SDS 7700 instrument using the end-point analysis mode of the SDS version 1.6.3 software package (ABI). The genotypes were determined visually based on the dye-component fluorescent emission data depicted in the X-Y scatter-plot of the SDS software. The genotypes were also determined automatically by the software's signal processing algorithms. The results of each scoring method were saved in 2 separate 
Biochemical Analysis
We measured the plasma concentration of total cholesterol and high-density lipoprotein (HDL) cholesterol and the serum concentration of creatinine and uric acid using standard methods employed by the Clinical Laboratory Department of Nihon University Hospital (13).
Statistical Analysis
All continuous variables are expressed as mean±SD. Differences in continuous variables between EH patients and control subjects were analyzed using the Mann-Whitney U-test. Differences in categorical variables were analyzed using Fisher's exact test. Hardy-Weinberg equilibrium was assessed by χ 2 analysis. Differences in distributions of genotypes and alleles between EH patients and control subjects were analyzed using Fisher's exact test. Based on the genotype data of the genetic variations, we performed linkage disequilibrium (LD) analysis and haplotype-based case-control analysis, using the expectation maximization (EM) algorithm (14) and the software SNPAlyze version 3.2 (Dynacom Co., Ltd., Yokohama, Japan) (15) . The SNP5 showed little heterogeneity as only one heterozygosity was found in the EH patients, therefore, SNP5 was not available for the haplotypebased case-control study. Pairwise LD analysis was performed using SNP1, SNP2, SNP3, and SNP4. We used |D′| values of ≥ 0.5 to assign SNP locations to 1 haplotype block. SNPs with an r 2 value of < 0.5 were selected as tagged, which means they were available for the haplotype. In the haplotype-based case-control analysis, haplotypes with a frequency of < 0.01 were excluded. With regard to this method, the general consensus is that the effect of less frequent haplotypes should be excluded (10, 12) . The analysis was also performed for each of the 3 groups: total population, men, and women. The frequency distribution of the haplotypes was calculated by χ 2 analysis. In addition, logistic regression analysis was performed to assess the contribution of the major risk factors. Statistical significance was established at p< 0.05. Statistical analyses were performed using SPSS software for Windows, version 12 (SPSS Inc., Chicago, USA). Table 1 shows the clinical characteristics of the study participants. For men, women, and total subjects, the following values were significantly higher in the EH patients than in the control subjects: body mass index (BMI), SBP, DBP, and pulse rate. For men and total subjects, serum uric acid and the prevalence of diabetes mellitus and smoking were significantly higher for the EH patients than the control subjects. For women and total subjects, the prevalence of drinking was higher in the EH group than in the control group. For the total subject group, total cholesterol was higher in the EH group as compared to the control group. There was no significant difference for any of the following variables between the EH patients and the control subjects: serum creatinine and the prevalence of hyperlipidemia. Table 2 shows the distribution of the genotypes and alleles of the 5 SNPs. The genotype distributions for each of the SNPs in the control subjects were in agreement with the predicted Hardy-Weinberg equilibrium values (data not shown). For the male subjects, the genotype distribution of SNP3 differed significantly between the EH patients and the control subjects (p= 0.013). For the total population and the men, the distribution of the dominant model of rs1558139 (CC vs. CT+TT) differed significantly between the EH patients and the control subjects (p= 0.037, p= 0.005, respectively), with the CC genotype higher in the EH patients than in the control subjects. For the male subjects, the C allele was significantly higher in the EH patients as compared to control subjects (p= 0.025). Table 3 shows the results of the logistic regression analysis. For the men, the frequency of the CC genotype of rs1558139 differed significantly between the EH patients and control subjects (p= 0.026), even after an adjustment for confounding factors such as BMI, diabetes mellitus, and smoking. However, for the total group, there were no differences noted for the frequency of the CC genotype of rs1558139 after adjustment for the aforementioned confounding factors (p= 0.247). Table 4 shows patterns of linkage disequilibrium for the CYP4F2 gene with |D′| and r 2 values. All 4 SNPs were located in 1 haplotype block because all |D′|≥ 0.5. Because the r 2 value of SNP1-SNP2≥ 0.5, it is not very effective for a haplotype-based case-control study when SNP1 and SNP2 are used simultaneously. In our haplotype-based case-control study, although the minor allele frequency of SNP1 in the controls was equal to that of SNP2, the minor allele frequency of SNP1 in the NCBI data was larger than that for SNP2. Therefore, we constructed haplotypes using SNP1, SNP3, and SNP4. In the haplotype-based case-control study, using SNP1, SNP3, and SNP4, 4 haplotypes were established in the total group, and 5 haplotypes were established in both the groups for men and women (Table 5 ). For men, the overall distribution of the haplotypes was significantly different between the EH patients and the control subjects (p= 0.042). In addition, for men, the frequency of the T-T-G haplotype was significantly lower in the EH patients as compared to that seen in the control subjects (p= 0.009).
Results
Discussion
It has been demonstrated that many CYP subfamilies are associated with EH, for example, CYP2J2, CYP2C9 (EET synthesis), CYP3A5 (metabolizes cortisol into 6β-hydroxycortisol), CYP4A11 (20-HETE synthesis), CYP8A (prostacyclin synthesis), and CYP11B2 (aldosterone synthesis) (8, (16) (17) (18) (19) (20) . In humans, the CYP4 subfamily mainly catalyzes AA to 20-HETE, which acts either in a prohypertensive or antihypertensive manner, depending on whether it is expressed at renovascular or tubular sites. In the renal tubule, 20-HETE blocks sodium transport and acts primarily as a natriuretic, antihypertensive substance. In the renal vasculature, 20-HETE has vasoconstricting and prohypertensive effects (6, 21) . CYP4A11 was first described as being able to catalyze AA into 20-HETE. Additionally, it was reported that the Cto-T mutation in the CYP4A11 gene influenced the production of 20-HETE, and that this was associated with EH in large human populations (8) . In our previous haplotype-based case-control study, we succeeded in identifying a haplotype of the CYP4A11 gene that was associated with EH in Japanese men (10) . Recently, immunoprecipitation studies using human kidney microsomes have shown that the CYP4F2 accounts for up to 70% of the 20-HETE production in humans. Therefore, CYP4F2-catalyzed 20-HETE formation is thought to be quantitatively more important than CYP4A11-catalyzed 20-HETE formation (5). The major difference between CYP4A11 and CYP4F2 with regard to function is that the CYP4F2 isoform is expressed in the liver, lung, and white blood cells and is also the main enzyme responsible for the ω-hydroxylation of leukotriene B4 (LTB4) (22) . A functional variant of the human CYP4F2 gene (rs2108622, V433M) that is capable of altering the production of 20-HETE has recently been identified (9) . Alterations in renal 20-HETE production that might contribute to the development of hypertension have been demonstrated in both animals and humans (7, 8) . Large population-based studies are needed to determine whether the functional variants of the CYP4F2 gene are related to the development of hypertension in humans. In our haplotype-based case-control study in Japanese subjects, we genotyped 5 SNPs in the CYP4F2 gene (including rs2108622) and assessed the association between the CYP4F2 gene and EH.
In the present study, we did not find any significant difference in the genotypic and allele distribution of SNP4 (rs2108622) in the total population, men, and women groups, while the distribution of the dominant model of SNP3 (rs1558139, CC vs. CT +TT) differed significantly between the EH patients and control subjects in the total population and in men (p= 0.037 and p= 0.005, respectively). When the logistic regression was adjusted for the BMI, diabetes mellitus, and smoking, the same results were observed in men (p= 0.026). However, for the total group, the difference between the EH patients and control subjects disappeared (p= 0.247). For men, the C allele was also significantly higher in EH patients compared to the control subjects (p= 0.025). These results indicate that the risk of EH is increased in men with the CC genotype and the C allele of SNP3. Additionally, the findings suggest that SNP3 might be a gender-specific genetic marker for EH. Only 1 CA heterozygous genotype of SNP5 (rs3093200) was found in 1 male EH patient. The clinical features for this patient were not different from the other EH patients.
Morris and Kaplan found that for genes with multiple susceptibilities, analysis based on haplotypes have advantages over analysis based on individual SNPs, particularly when linkage disequilibria between the SNPs are weak (23) . For men, the overall distribution of the haplotypes were significantly different between the EH patients and the control subjects (p= 0.042). In addition, the frequency of the T-T-G haplotype constructed with SNP1, SNP3, and SNP4 for men was also significantly lower for EH patients as compared to the control subjects, and thus, the T-T-G haplotype is a protective haplotype in men. In the present study, although SNP4 (rs2108622) was not associated with EH, we successfully isolated the significant haplotypes. This result suggests that there is a possible mutation that has an effect on the production of 20-HETE associated with EH rather than SNP4 because the haplotype-based case-control study is a more powerful tool than the simple case-control study that uses each SNP (24) . This mutation may be linked to the significant haplotype.
Some case-control studies have identified gene variants associated with gender-specific susceptibility to EH (24, 25) . Animal experiments have revealed that the expression of the number of P450 enzymes is sex-dependent (26, 27) . The present haplotype-based case-control study also showed gender-specific (for men only) genotype and haplotype significant differences between the EH patients and the control subjects. This is very interesting in light of previous findings that showed that male cyp4a14 − / − or cyp4a10 − / − mice have higher BP than female cyp4a14 − / − or cyp4a10 − / − mice, respectively. The male cyp4a14 − / − mice exhibited increases in plasma androgen, and their hypertensive phenotype was found to be androgen sensitive (28, 29) . Cyp4a14 and cyp4a10 do not exist in humans, but as human CYP4A11 is 72.69% identical with murine cyp4a14 and 73.02% identical with murine cyp4a10 by amino acid sequence, murine cyp4a14 and cyp4a10 can therefore be regarded as being homologous to human CYP4A11. Unfortunately, there has yet to be a knockout animal model established for the CYP4F gene that includes cyp4f2. In the current experiment, we also did not obtain plasma androgen data because we were not able to obtain informed consent to collect blood samples for the purpose of measuring the plasma androgen levels. When all of the current results are taken together, our findings suggest that SNP3 (rs1558139) and the T-T-G haplotype might be associated with the androgen-mediated activity of the CYP4F2 enzyme.
In conclusion, the CC genotype and the C allele of rs1558139 in the human CYP4F2 gene might be susceptibility markers. In addition, the T-T-G haplotype appears to be a protective marker for EH in Japanese men. However, due to the moderate size of the population examined in this study, in order to be able to conclusively discuss the statistical significance of the interaction between the genotype (or haplotype) and the phenotype, further studies based on larger populations are needed. Such studies would allow us to isolate the functional mutations of the CYP4F2 gene that regulate BP, and to evaluate the function of the CYP4F2 variants that are involved in the metabolism of sex hormones.
